Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is to evaluate absolute change from baseline in hepatic fat fraction assessed by Magnetic Resonance Imaging – Proton Density Fat Fraction (MRI-PDFF) at Week 12
Dr. Rama Behara, DO
Akero Therapeutics, Inc.
Type of Trial